Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
BTLA
BTN2A1
BTN3A1
Butyrophilins
HGSOC
Immune checkpoints
PD-1
PD-L1
Prognostic biomarkers
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
13 May 2023
13 May 2023
Historique:
received:
12
01
2023
accepted:
03
05
2023
medline:
15
5
2023
pubmed:
14
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
The most common subtype of ovarian cancer (OC) showing immunogenic potential is represented by the high-grade serous ovarian cancer (HGSOC), which is characterized by the presence of tumor-infiltrating immune cells able to modulate immune response. Because several studies showed a close correlation between OC patient's clinical outcome and expression of programmed cell death protein-1 or its ligand (PD-1/PD-L1), the aim of our study was to investigate if plasma levels of immunomodulatory proteins may predict prognosis of advanced HGSOC women. Through specific ELISA tests, we analyzed plasma concentrations of PD-L1, PD-1, butyrophilin sub-family 3A/CD277 receptor (BTN3A1), pan-BTN3As, butyrophilin sub-family 2 member A1 (BTN2A1), and B- and T-lymphocyte attenuator (BTLA) in one hundred patients affected by advanced HGSOC, before surgery and therapy. The Kaplan-Meier method was used to generate the survival curves, while univariate and multivariate analysis were performed using Cox proportional hazard regression models. For each analyzed circulating biomarker, advanced HGSOC women were discriminated based on long (≥ 30 months) versus short progression-free survival (PFS < 30 months). The concentration cut-offs, obtained by receiver operating characteristic (ROC) analysis, allowed to observe that poor clinical outcome and median PFS ranging between 6 and 16 months were associated with higher baseline levels of PD-L1 (> 0.42 ng/mL), PD-1 (> 2.48 ng/mL), BTN3A1 (> 4.75 ng/mL), pan-BTN3As (> 13.06 ng/mL), BTN2A1 (> 5.59 ng/mL) and BTLA (> 2.78 ng/mL). Furthermore, a lower median PFS was associated with peritoneal carcinomatosis, age at diagnosis > 60 years or Body Mass Index (BMI) > 25. A multivariate analysis also suggested that plasma concentrations of PD-L1 ≤ 0.42 ng/mL (HR: 2.23; 95% CI: 1.34 to 3.73; p = 0.002), age at diagnosis ≤ 60 years (HR: 1.70; 95% CI: 1.07 to 2.70; p = 0.024) and absence of peritoneal carcinomatosis (HR: 1.87; 95% CI: 1.23 to 2.85; p = 0.003) were significant prognostic marker for a longer PFS in advanced HGSOC patients. The identification of high-risk HGSOC women could be improved through determination of the plasma PD-L1, PD-1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels.
Sections du résumé
BACKGROUND
BACKGROUND
The most common subtype of ovarian cancer (OC) showing immunogenic potential is represented by the high-grade serous ovarian cancer (HGSOC), which is characterized by the presence of tumor-infiltrating immune cells able to modulate immune response. Because several studies showed a close correlation between OC patient's clinical outcome and expression of programmed cell death protein-1 or its ligand (PD-1/PD-L1), the aim of our study was to investigate if plasma levels of immunomodulatory proteins may predict prognosis of advanced HGSOC women.
PATIENTS AND METHODS
METHODS
Through specific ELISA tests, we analyzed plasma concentrations of PD-L1, PD-1, butyrophilin sub-family 3A/CD277 receptor (BTN3A1), pan-BTN3As, butyrophilin sub-family 2 member A1 (BTN2A1), and B- and T-lymphocyte attenuator (BTLA) in one hundred patients affected by advanced HGSOC, before surgery and therapy. The Kaplan-Meier method was used to generate the survival curves, while univariate and multivariate analysis were performed using Cox proportional hazard regression models.
RESULTS
RESULTS
For each analyzed circulating biomarker, advanced HGSOC women were discriminated based on long (≥ 30 months) versus short progression-free survival (PFS < 30 months). The concentration cut-offs, obtained by receiver operating characteristic (ROC) analysis, allowed to observe that poor clinical outcome and median PFS ranging between 6 and 16 months were associated with higher baseline levels of PD-L1 (> 0.42 ng/mL), PD-1 (> 2.48 ng/mL), BTN3A1 (> 4.75 ng/mL), pan-BTN3As (> 13.06 ng/mL), BTN2A1 (> 5.59 ng/mL) and BTLA (> 2.78 ng/mL). Furthermore, a lower median PFS was associated with peritoneal carcinomatosis, age at diagnosis > 60 years or Body Mass Index (BMI) > 25. A multivariate analysis also suggested that plasma concentrations of PD-L1 ≤ 0.42 ng/mL (HR: 2.23; 95% CI: 1.34 to 3.73; p = 0.002), age at diagnosis ≤ 60 years (HR: 1.70; 95% CI: 1.07 to 2.70; p = 0.024) and absence of peritoneal carcinomatosis (HR: 1.87; 95% CI: 1.23 to 2.85; p = 0.003) were significant prognostic marker for a longer PFS in advanced HGSOC patients.
CONCLUSIONS
CONCLUSIONS
The identification of high-risk HGSOC women could be improved through determination of the plasma PD-L1, PD-1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels.
Identifiants
pubmed: 37179293
doi: 10.1186/s12885-023-10911-5
pii: 10.1186/s12885-023-10911-5
pmc: PMC10183131
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
B7-H1 Antigen
0
BTN3A1 protein, human
0
Butyrophilins
0
Antigens, CD
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437Informations de copyright
© 2023. The Author(s).
Références
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1161-1169
pubmed: 31030490
Br J Cancer. 2006 Nov 20;95(10):1314-20
pubmed: 17088903
Gynecol Oncol. 2012 Nov;127(2):367-74
pubmed: 22800653
Cancers (Basel). 2022 Aug 13;14(16):
pubmed: 36010904
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Diagnostics (Basel). 2022 Jan 13;12(1):
pubmed: 35054356
NPJ Breast Cancer. 2022 Nov 9;8(1):121
pubmed: 36351947
Nat Rev Immunol. 2014 Aug;14(8):559-69
pubmed: 25060581
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1307-10
pubmed: 15894691
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Cancer Cell Int. 2023 Jan 25;23(1):11
pubmed: 36698173
Cancers (Basel). 2020 Oct 06;12(10):
pubmed: 33036192
Sci Rep. 2021 Oct 5;11(1):19712
pubmed: 34611279
Acta Obstet Gynecol Scand. 2010;89(1):101-7
pubmed: 19878086
Cancers (Basel). 2022 Sep 06;14(18):
pubmed: 36139508
J Transl Med. 2023 Jan 13;21(1):25
pubmed: 36639643
Oncoimmunology. 2019 Feb 3;8(4):e1561120
pubmed: 30906655
J Histochem Cytochem. 2018 Feb;66(2):67-83
pubmed: 29164988
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Transl Oncol. 2021 Feb;14(2):100994
pubmed: 33333370
Obstet Gynecol Sci. 2020 May;63(3):346-356
pubmed: 32489980
PLoS One. 2019 Feb 26;14(2):e0212978
pubmed: 30807610
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158899
Cancer. 2006 Oct 1;107(7):1520-4
pubmed: 16941453
Cancers (Basel). 2020 Nov 16;12(11):
pubmed: 33207823
Cancer Immunol Immunother. 2014 Mar;63(3):215-24
pubmed: 24297569
Sci Rep. 2019 Jul 31;9(1):11131
pubmed: 31366979
Adv Ther. 2019 Oct;36(10):2600-2617
pubmed: 31432460
Ther Adv Med Oncol. 2019 May 13;11:1758835919848872
pubmed: 31205506
Cancers (Basel). 2021 Apr 27;13(9):
pubmed: 33925671
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35131863
Ann Oncol. 2019 Jul 1;30(7):1025-1028
pubmed: 31111866
Front Immunol. 2021 Aug 09;12:705096
pubmed: 34434192
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Int J Gynecol Cancer. 2015 Jun;25(5):815-22
pubmed: 25768081
Oncoimmunology. 2020 Oct 27;9(1):1832348
pubmed: 33178494
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
PLoS One. 2018 Mar 26;13(3):e0194993
pubmed: 29579127
Front Oncol. 2016 Mar 24;6:63
pubmed: 27047797
Best Pract Res Clin Obstet Gynaecol. 2022 Jan;78:64-73
pubmed: 34607745
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Expert Opin Drug Saf. 2018 Dec;17(12):1197-1209
pubmed: 30457416
J Ovarian Res. 2021 Aug 28;14(1):112
pubmed: 34454562
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Sci Rep. 2021 Feb 12;11(1):3750
pubmed: 33580098
NPJ Precis Oncol. 2022 Jan 27;6(1):7
pubmed: 35087175
J Ovarian Res. 2014 Apr 22;7:41
pubmed: 24834130
Front Oncol. 2022 Sep 21;12:946319
pubmed: 36212445
Front Oncol. 2019 Oct 15;9:1073
pubmed: 31681606